Literature DB >> 9525635

Type D retrovirus capsid assembly and release are active events requiring ATP.

R A Weldon1, W B Parker, M Sakalian, E Hunter.   

Abstract

Mason-Pfizer monkey virus (M-PMV), the prototype type D retrovirus, differs from most other retroviruses by assembling its Gag polyproteins into procapsids in the cytoplasm of infected cells. Once assembled, the procapsids migrate to the plasma membrane, where they acquire their envelope during budding. Because the processes of M-PMV protein transport, procapsid assembly, and budding are temporally and spatially unlinked, we have been able to determine whether cellular proteins play an active role during the different stages of procapsid morphogenesis. We report here that at least two stages of morphogenesis require ATP. Both procapsid assembly and procapsid transport to the plasma membrane were reversibly blocked by treating infected cells with sodium azide and 2-deoxy-D-glucose, which we show rapidly and reversibly depletes cellular ATP pools. Assembly of procapsids in vitro in a cell-free translation/assembly system was inhibited by the addition of nonhydrolyzable ATP analogs, suggesting that ATP hydrolysis and not just ATP binding is required. Since retrovirus Gag polyproteins do not bind or hydrolyze ATP, these results demonstrate that cellular components must play an active role during retrovirus morphogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525635      PMCID: PMC109760     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Form, function, and use of retroviral gag proteins.

Authors:  J W Wills; R C Craven
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

Review 2.  Molecular chaperones in cellular protein folding.

Authors:  F U Hartl
Journal:  Nature       Date:  1996-06-13       Impact factor: 49.962

3.  HIV-1 Gag protein associates with F-actin present in microfilaments.

Authors:  O Rey; J Canon; P Krogstad
Journal:  Virology       Date:  1996-06-15       Impact factor: 3.616

4.  Refined solution structure of p17, the HIV matrix protein.

Authors:  S Matthews; P Barlow; N Clark; S Kingsman; A Kingsman; I Campbell
Journal:  Biochem Soc Trans       Date:  1995-11       Impact factor: 5.407

5.  Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions.

Authors:  C A Deminie; M Emerman
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins.

Authors:  R P Bennett; T D Nelle; J W Wills
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.

Authors:  W Zhou; L J Parent; J W Wills; M D Resh
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

8.  The solution structure of the bovine leukaemia virus matrix protein and similarity with lentiviral matrix proteins.

Authors:  S Matthews; M Mikhailov; A Burny; P Roy
Journal:  EMBO J       Date:  1996-07-01       Impact factor: 11.598

9.  A eukaryotic cytosolic chaperonin is associated with a high molecular weight intermediate in the assembly of hepatitis B virus capsid, a multimeric particle.

Authors:  J R Lingappa; R L Martin; M L Wong; D Ganem; W J Welch; V R Lingappa
Journal:  J Cell Biol       Date:  1994-04       Impact factor: 10.539

10.  Function in protein folding of TRiC, a cytosolic ring complex containing TCP-1 and structurally related subunits.

Authors:  J Frydman; E Nimmesgern; H Erdjument-Bromage; J S Wall; P Tempst; F U Hartl
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  20 in total

1.  ATP-Dependent localization of the herpes simplex virus capsid protein VP26 to sites of procapsid maturation.

Authors:  J H Chi; D W Wilson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  ATP is required for correct folding and disulfide bond formation of rotavirus VP7.

Authors:  A Mirazimi; L Svensson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process.

Authors:  M Tritel; M D Resh
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 4.  How HIV-1 Gag assembles in cells: Putting together pieces of the puzzle.

Authors:  Jaisri R Lingappa; Jonathan C Reed; Motoko Tanaka; Kasana Chutiraka; Bridget A Robinson
Journal:  Virus Res       Date:  2014-07-24       Impact factor: 3.303

5.  ATP depletion blocks herpes simplex virus DNA packaging and capsid maturation.

Authors:  A Dasgupta; D W Wilson
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

6.  A cell-line-specific defect in the intracellular transport and release of assembled retroviral capsids.

Authors:  S D Parker; E Hunter
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission.

Authors:  I Le Blanc; A R Rosenberg; M C Dokhélar
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain.

Authors:  S Campbell; A Rein
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release.

Authors:  Eva Gottwein; Jochen Bodem; Barbara Müller; Ariane Schmechel; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Increased ATP generation in the host cell is required for efficient vaccinia virus production.

Authors:  Chia-Wei Chang; Hui-Chun Li; Che-Fang Hsu; Chiao-Yen Chang; Shih-Yen Lo
Journal:  J Biomed Sci       Date:  2009-09-02       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.